Tools
Stock profile

BRISTOL MYERS SQUIBB CO (BMY)

BMY · Latest close $59.56 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$59.56
As of Nov 18, 2026
Tracked funds holding
14 of 149
2026 Q2 13F filings
Opened / added
0 / 5
vs previous quarter
Trimmed / exited
5
vs previous quarter

BRISTOL MYERS SQUIBB CO (BMY) is held by 14 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 5 funds adding and 5 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $677.8K sold). 0 members of Congress reported 0 purchases vs 1 sale. Latest close $59.56 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 5, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-677.8K
Congress
0 buys vs 1 sale
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Independent Franchise Partners · Pzena Investment Management · Hillman Capital Management — 14 tracked funds hold BMY. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 3 sales ($677.8K). Insider trading 0 members of Congress reported buying (0 purchases vs 1 sale). Politician trading

Often held alongside

REGIONS FINANCIAL CORP (RF) · GILEAD SCIENCES, INC. (GILD) · KB Financial Group Inc. (KB) · TARGET CORP (TGT) · GSK plc (GSK) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Independent Franchise Partners8.24%21,792,841ADDED (+2.4%) Q3 filed Nov 13
Pzena Investment Management2.88%17,007,044TRIMMED (-0.5%) Q3 filed Oct 30
Hillman Capital Management1.89%45,235TRIMMED (-14.8%) Q3 filed Nov 16
Kahn Brothers Group1.59%174,152ADDED (+2.2%) Q3 filed Nov 16
OrbiMed Advisors0.99%925,000HELD Q3 filed Nov 16
Miller Value Partners0.95%69,500HELD Q3 filed Nov 16
Ariel Investments0.40%696,430TRIMMED (-3.5%) Q3 filed Nov 13
Tweedy Browne0.16%37,570ADDED (+43.6%) Q3 filed Nov 4
Thornburg Investment Management0.02%38,400HELD Q3 filed Nov 13
Mairs & Power Funds0.01%24,684ADDED (+2.0%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +8.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

68.0941.582024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

242019Q4: 18 funds2020Q1: 18 funds2020Q2: 21 funds2020Q3: 24 funds2020Q4: 22 funds2021Q1: 21 funds2021Q2: 21 funds2021Q3: 21 funds2021Q4: 20 funds2022Q1: 19 funds2022Q2: 18 funds2022Q3: 18 funds2022Q4: 17 funds2025Q1: 17 funds2019Q42025Q1

Tracked funds holding this stock, by quarter (2019Q4–2025Q1, 14 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding2,526 of 8,857 filers
Long-only filers among them2,510
Change vs 2026 Q1+20 net · 1,781 entered · 1,761 exited
Shares reported, all filers1,663,846,841
Reported value, all filers$93.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$48.2B
Net income · FY2025$7.1B
Total assets · FY2025$90.0B
Shares outstanding2,044,085,831
Market cap (at latest close)$121.7B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 21, 2026.

Short interest

Shares short · Oct 15, 202649,948,083
Share of shares outstanding2.44%
Days to cover3.65

Shares short at recent settlements — Jul 31, 2026: 52.3M · Aug 14, 2026: 45.9M · Aug 31, 2026: 44.1M · Sep 15, 2026: 42.0M · Sep 30, 2026: 45.8M · Oct 15, 2026: 49.9M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 21, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 2026909
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 2026<0.1%

Fails to deliver at recent settlements — Jul 31, 2026: 63K · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 909.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 21, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 3 sales by 3 insiders ($677.8K).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 5, 2026Haller Julia ASell3,800$63.31$240.6KSEC filing
Sep 9, 2026Massacesi CristianEVP,Chief Med Offr,Head of DevSell6,249$64.57$403.5KSEC filing
Aug 25, 2026Holzer Phil MSVP and ControllerSell500$67.50$33.8KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 9, 2026Massacesi CristianOfficer6,249$403.5KSep 9, 2026SEC filing
Aug 25, 2026Holzer Phil MOfficer500$33.8KAug 25, 2026SEC filing
Apr 1, 2026Elkins David VOfficer30,000$1.9MApr 1, 2026SEC filing
Sep 2, 2025Elkins David VOfficer56,000$2.6MSep 2, 2025SEC filing
Nov 4, 2024Holzer Phil MOfficer700$38.9KNov 4, 2024SEC filing
Aug 24, 2023Powell AnnOfficer17,986$1.1MAug 24, 2023SEC filing
Aug 3, 2023Plenge Robert MOfficer732$44.8KAug 3, 2023SEC filing
May 3, 2023VESSEY RUPERTOfficer50,385$3.4MMay 3, 2023SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 7, 2026STATE STREET CORPORATIONSC 13G102,521,7485.0%Jun 30, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G153,108,0187.5%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Oct 31, 2025SC 13G/A———SEC filing
Apr 25, 2025JPMORGAN CHASE & CO.SC 13G104,688,4975.1%Mar 31, 2025SEC filing
Apr 17, 2025BlackRock, Inc.SC 13G/A143,574,2307.1%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

0 members of Congress reported buying (0 purchases vs 1 sale).

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Kelly, MikeHouseR01May 7, 2026$15,001 - $50,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 541 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (347), Medicare/Medicaid (316), Taxation/Internal Revenue Code (190).

Federal contracts: $21.1M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$12.0K
FY2022$312.7K
FY2023$947.2K
FY2024$3.4M
FY2025$7.6M
FY2026$8.8M

Largest awards collected

Award IDAgencyAmountStart
36C25226N0198Department of Veterans Affairs$848.4KDec 31, 2025
36C24825N0730Department of Veterans Affairs$670.1KMay 15, 2025
36C24926N0651Department of Veterans Affairs$378.7KAug 10, 2026
36C24926F0096Department of Veterans Affairs$378.7KMar 13, 2026
36C24526N0290Department of Veterans Affairs$371.3KJan 29, 2026

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Dividend Growth — Dividends raised for more than 10 years

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Shareholder Yield — Cash returned through dividends and buybacks

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

Key figures

· Dividend Growth — Dividend per share: 2.49 · Dividend yield: 4.1% · Straight dividend years: 19 · 10-yr dividend growth: 62.7%

· Cash Flow (FCF) — Latest FCF: $12.8B · FCF yield: 10.3% · Positive FCF years: 3

· Shareholder Yield — Shareholder yield: 4.0% · of which dividends: 4.0% · of which buybacks: 0.0%

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 14 of the last 40 quarterly lists; latest 2025 Q1, ranked #43 of 50.

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2023 Q4, ranked #42 of 50.

· Politician BEST — appeared in 2 of the last 20 quarterly lists; latest 2024 Q4, ranked #23 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together1154.5%+4.8%+2.5%+2.4%
Share count tripled (3x)10.0%-4.6%+5.7%-10.3%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold BMY — ranked by lift, the co-holding pattern described in Methodology: REGIONS FINANCIAL CORP (RF) · GILEAD SCIENCES, INC. (GILD) · KB Financial Group Inc. (KB) · TARGET CORP (TGT) · GSK plc (GSK) · RESIDEO TECHNOLOGIES, INC. (REZI) · AT&T INC. (T) · VERIZON COMMUNICATIONS INC (VZ).

Recent 8-K filings

FiledItemsSource
Oct 29, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Jul 30, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
May 8, 20265.07 Submission of Matters to a Vote of Security HoldersSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

REGIONS FINANCIAL CORP (RF) · Track Record: how the signals scored · Practice timing on BMY

One email a week: the week’s new filings and research. Subscribe free

← BMRN  ·  BN →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.